Shigella – S4V

Shigellosis, caused by Shigella bacteria, is the second leading cause of fatal diarrheal disease worldwide. It is estimated that up to 165 million cases of disease and an estimated 600,000 deaths are attributed to Shigella each year [1], particularly among children in Low- and Middle-Income Countries.

S4V – The World’s Most Clinically Advanced Tetravalent Shigella Vaccine Candidate

  • Shigella4V (S4V) is a tetravalent bioconjugate vaccine candidate against shigellosis.
  • Valneva in-licensed S4V as part of an exclusive worldwide development, manufacturing, and commercialization agreement with LimmaTech Biologics AG [2].
  • No approved Shigella vaccine is currently available and the development of Shigella vaccines has been identified as a priority by the World Health Organization [3].
  • In addition to the local LMICs populations, Shigellosis also affects international travelers from high-income countries and deployed military personnel in endemic regions.
  • LimmaTech reported positive Phase 1/2 results for S4V, including a favorable safety and tolerability profile as well as robust data on immunogenicity against the four most common pathogenic Shigella serotypes, S. flexneri 2a, 3a, 6, and S. sonnei [4].
  • LimmaTech will conduct two Phase 2 studies in LMICs which are expected to begin in the second half of 2024.

 

Additional information about Shigella:

View Valneva’s press releases about S4V

[1] Shigellosis | CDC Yellow Book 2024

[2] Press Release: Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World’s Most Clinically Advanced Tetravalent Shigella Vaccine Candidate

[3] https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases/shigella

[4] Press Release: LimmaTech Biologics Reports Positive Interim Phase I/II Clinical Data on Tetravalent Shigella Bioconjugate Vaccine S4V